Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq and Avastin maintenance in TP53-mutant ovarian cancer
NCT04510584Phase 2Withdrawn
- Sponsor
- University Health Network
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University Health Network. Primary endpoint: Number of participants where increase in circulating deoxyribonucleic acid (ctDNA) level is related to progression at 3 months. Planned start Jul 2021; status: withdrawn.
02
Drugs
atezolizumabbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04510584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510584.